New Zealand markets closed

BIIB Mar 2023 360.000 call

OPR - OPR Delayed price. Currency in USD
Add to watchlist
0.80000.0000 (0.00%)
As of 10:47AM EST. Market open.
Full screen
Previous close0.8000
Open0.8000
Bid0.0000
Ask0.0000
Strike360.00
Expiry date2023-03-17
Day's range0.8000 - 0.8000
Contract rangeN/A
Volume3
Open interestN/A
  • GlobeNewswire

    Marketing Authorization Application for Lecanemab as Treatment for Early Alzheimer’s Disease Accepted by European Medicines Agency

    TOKYO and CAMBRIDGE, Mass., Jan. 26, 2023 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, "Biogen") announced today that the European Medicines Agency (EMA) has accepted a marketing authorization application (MAA) for lecanemab (Brand Name in the U.S.: LEQEMBI™), an investigational anti-amyloid beta (Aβ) protofibril* antibody, for the treatment of

  • Motley Fool

    Is Biogen Stock a Buy Now?

    Moving new medicines to the market can sometimes make biopharmaceutical companies tons of returns. Biogen (NASDAQ: BIIB) just scored a major new drug approval for an Alzheimer's disease therapy, so investors are understandably rushing to evaluate whether to buy the stock. One key factor that could drive Biogen's outperformance in the next few years is the launch of a new neurology medicine.

  • Motley Fool

    Is Biogen Stock a No-Brainer Buy After Eli Lilly's Alzheimer's Disease Setback?

    Lilly's FDA rejection puts Biogen and its partner Eisai in the driver's seat in the Alzheimer's disease drug market.